Explained: India's Total Covid Vaccine Orders So Far And Its Plan To Procure 267.6 Crore Doses By December
The Health Ministry in its briefing on Thursday (13 May) provided the details of India's Covid-19 vaccine procurement so far and the road-map charted out to procure a total of 267.6 crore doses by December.
A total of 35.6 crore vaccine doses have been procured by the centre so far and procurement of 16.6 crore additional doses by various states and private hospitals are in the pipeline.
This takes the tally of planned vaccine procurement to 51.6 crore doses which will cover approximately 19 per cent of the population.
Out of the 35.6 crore doses for the centre, 27.6 crore doses are of Serum Institute's Covishield and 8 crore are of Covaxin. Here's their breakup.
6.6 crore doses have been ordered under PM-CARES fund out of which 5.6 crore are Covishield. Similarly 1 crore Covishield doses were ordered under GAVI. The doses have been fully utilised.
In Phase-II of the vaccine procurement, the centre ordered 12 crore doses (10 crore of Covishield and 2 crore of Covaxin). 86 per cent of the doses have been received with the delivery completion expected by May end.
Under Phase-III the centre has ordered 16 crore doses (11 crore Covishield, and 5 crore Covaxin) which will be delivered by July end.
The Health Ministry has also shared a tentative estimate that almost 216 crore vaccine doses could be made available between August and December, which on paper should be enough to cover virtually the entirety of the Indian population.
As per the chart, India is expected to get 75 crore doses of Covishield, 55 crore doses of Covaxin and 15.6 crore doses of Sputnik V vaccine. These vaccines have received DGCI nod so far. The remaining 70.5 crore doses are expected to be supplied by under-development vaccines like Novivax, Zydus Cadilia, Bharat Biotech Nasal Spray and others.
In addition to these estimates, India may also receive doses of foreign makers. States like Uttar Pradesh, West Bengal, Rajasthan, Maharashtra and Odisha have floated global tenders to procure vaccines. Moderna and Johnson & Johnson may participate in these tenders.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.